News & Updates

In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.

Treatment with dapagliflozin results in improvements in all outcomes, regardless of frailty status, among patients with symptomatic heart failure (HF) with reduced ejection fraction, reports a study. However, “more frail” patients have larger absolute reductions.

An annual influenza vaccination does not lower the risk of cardiovascular (CV) outcomes in patients with heart failure (HF), though it may reduce the risk of pneumonia and hospitalization, according to results of the IVVE study presented at ACC.22.

In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.

A more intensive serum urate-lowering therapy falls short of improving bone erosion scores in patients with erosive gout, in addition to being associated with a high treatment burden, as shown in a study.